Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens
currently in clinical use. However, the precise mechanisms of DOX's action are not fully …

As immunogenic cell death (ICD) inducers initiating antitumor immune responses, certain
chemotherapeutic drugs have shown considerable potential to reverse the …

The last decade witnessed the great advances in the development of nanomedicines. As a
kind of attractive nanomedicine, carrier-free nanomedicines received extensive …

Immunogenic cell death (ICD, also known as immunogenic apoptosis) of malignant cells is
confirmed to activate the host immune system to prevent, control, and eliminate tumors …

Peptides can self‐assemble into various hierarchical nanostructures through noncovalent
interactions and form functional materials exhibiting excellent chemical and physical …

Rationale: Cancer immunotherapy combining immune checkpoint blockade (ICB) with
chemotherapeutic drugs has provided significant clinical advances. However, such …

Cancer immunotherapy, despite its enormous application prospect, is trapped in the
abnormal lactic acid metabolism of tumor cells that usually causes an immunosuppressive …

The chemotherapeutic drug of doxorubicin (DOX) has witnessed widespread applications
for treating various cancers. DOX-treated dying cells bear cellular modifications which allow …

The efficacy of combination immunotherapy has been limited by tumor specificity and
immune‐related adverse events (irAEs). Herein, we report the development of polymeric …

Currently, immune checkpoint blockade (ICB) therapies that target the programmed cell
death ligand-1 (PD-L1) have been used as revolutionary cancer treatments in the clinic …